• Immuron launches PROIBS, a certified medical device for treating IBS symptoms
• PROIBS contains AVH200 derived from Aloe barbadensis, supporting the intestinal mucosal barrier
• Usability study showed PROIBS was helpful for 94% of users, with 91% experiencing improved daily life

Immuron Limited, an Australian based and globally integrated biopharmaceutical company, has announced the official launch of PROIBS® into the Australian market. PROIBS® is a certified medical device for the treatment of Irritable Bowel Syndrome (IBS) symptoms such as abdominal pain, bloating and unsettled bowel movements (diarrhoea and/or constipation). PROIBS® contains AVH200®, derived from the plant Aloe barbadensis. Mill. AVH200® has gel forming components which support the intestinal mucosal barrier. As IBS is known to affect individuals for a long period of time, it is essential to have a treatment appropriate for long-term use, which PROIBS® is. The product is safe, and no interactions with other medications are known. A usability study conducted among 1,003 users showed that PROIBS® was helpful for 94% of them, 91% experienced an improvement in daily life, and 98% would recommend PROIBS® to someone else. Immuron has been a leader in digestive health in Australia for many years, and PROIBS® will join Immuron's product portfolio, which includes the rapidly growing Travelan® brand, building on the premium efficacy product range that will deliver better outcomes for consumers that Pharmacists will love to recommend.

Immuron expects the IBS treatment market in Australia to be part of the broader 'Digestives & Intestinal Remedies' market, generating a revenue of around AU$221.14 million in 2025, with a projected annual growth rate of 3.28%.

Immuron is focused on the accelerated launch of PROIBS® in Australia, targeting the peak festive season where IBS symptom triggers are highest. The launch will focus on online and selected pharmacies, supported by an awareness and trial campaign across digital marketing and social media.